NBTXR 3

Drug Profile

NBTXR 3

Alternative Names: Hafnium Oxide nanoparticles; NBTX 3; NBTXR-3; PEP-503

Latest Information Update: 23 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nanobiotix
  • Developer Nanobiotix; PharmaEngine
  • Class Antineoplastics; Radiosensitisers
  • Mechanism of Action Free radical stimulants; Radiography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Phase II/III Soft tissue sarcoma
  • Phase I/II Head and neck cancer; Prostate cancer; Rectal cancer
  • Preclinical Hepatocellular carcinoma; Solid tumours

Most Recent Events

  • 15 Jun 2017 Pharmacodynamics data from a phase II/III trial and a preclinical trial in Soft tissue sarcoma released by Nanobiotix
  • 18 May 2017 Pharmacodynamics data from a phase II/III trial in Soft tissue sarcoma released by Nanobiotix
  • 01 Apr 2017 NBTXR 3 is still in preclinical development for Solid tumours in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top